ADC Therapeutics SA
ADCT
$1.89
$0.2011.83%
NYSE
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 36.21% | -8.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 36.21% | -8.42% | |||
| Cost of Revenue | -98.13% | 5,880.18% | |||
| Gross Profit | 122.49% | -660.97% | |||
| SG&A Expenses | -1.75% | 0.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.36% | -8.67% | |||
| Operating Income | 12.25% | 8.80% | |||
| Income Before Tax | -23.80% | 29.24% | |||
| Income Tax Expenses | 151.40% | -456.67% | |||
| Earnings from Continuing Operations | -25.63% | 30.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.63% | 30.12% | |||
| EBIT | 12.25% | 8.80% | |||
| EBITDA | 12.38% | 8.89% | |||
| EPS Basic | -23.53% | 30.51% | |||
| Normalized Basic EPS | -21.73% | 29.63% | |||
| EPS Diluted | -23.53% | 30.51% | |||
| Normalized Diluted EPS | -21.73% | 29.63% | |||
| Average Basic Shares Outstanding | 1.71% | 0.55% | |||
| Average Diluted Shares Outstanding | 1.71% | 0.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||